|
|
 |
|
|
|
 |
| Market Cap | 9.69B | EPS (ttm) | -1.72 |
| P/E | - | EPS this Y | -120.60% |
| Forward P/E | - | EPS next Y | 50.90% |
| PEG | - | EPS past 5Y | -29.10% |
| P/S | 475.08 | EPS next 5Y | 64.80% |
| P/B | 16.06 | EPS Q/Q | 25.50% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 0.10% | Inst Own | 90.70% |
| Insider Trans | - | Inst Trans | 15.53% |
| Short Float | 12.72% | Earnings | Aug 05/a |
| Analyst Recom | 1.80 | Target Price | 52.24 |
| Avg Volume | 2.54M | 52W Range | 8.80 - 45.69 |
|
|
|
|
| Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company has clinical collaboration with AstraZeneca, MedImmune, and Roche; collaboration agreement with The Bayer Group; clinical and preclinical collaborations with academic cancer institutions; and research collaboration with the Memorial Sloan Kettering Cancer Center. It also has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Duncan Barbara Gayle | Director | Aug 17 | Option Exercise | 16.96 | 20,000 | 339,200 | 37,077 | Aug 20 04:15 PM | | Duncan Barbara Gayle | Director | Aug 12 | Option Exercise | 12.93 | 17,077 | 220,806 | 17,077 | Aug 14 04:33 PM | | Avoro Capital Advisors LLC | Director | May 01 | Buy | 28.50 | 1,750,000 | 49,875,000 | 26,250,000 | May 01 10:20 AM | | Avoro Capital Advisors LLC | Director | Dec 05 | Buy | 17.50 | 2,000,000 | 35,000,000 | 24,500,000 | Dec 09 04:05 PM | | BALL BRYAN | Chief Quality Officer | Oct 03 | Buy | 14.18 | 5,000 | 70,897 | 10,000 | Oct 03 05:30 PM |
|
|
|
 |
| Market Cap | 36.50M | EPS (ttm) | -1.41 |
| P/E | - | EPS this Y | 41.80% |
| Forward P/E | - | EPS next Y | 21.70% |
| PEG | - | EPS past 5Y | -22.90% |
| P/S | - | EPS next 5Y | - |
| P/B | - | EPS Q/Q | 74.40% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 1.70% | Inst Own | 1.10% |
| Insider Trans | 0.00% | Inst Trans | 14.10% |
| Short Float | 4.11% | Earnings | - |
| Analyst Recom | 2.00 | Target Price | - |
| Avg Volume | 922.60K | 52W Range | 0.38 - 1.63 |
|
|
|
|
| Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California. |
|
|
 |
| Market Cap | 353.54M | EPS (ttm) | -0.39 |
| P/E | - | EPS this Y | 1.80% |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | 9.80% |
| P/S | 110.48 | EPS next 5Y | 12.50% |
| P/B | 1.72 | EPS Q/Q | -10.20% |
| Dividend | - | Sales Q/Q | 0.00% |
| Insider Own | 25.50% | Inst Own | 19.90% |
| Insider Trans | 0.00% | Inst Trans | -4.82% |
| Short Float | 1.26% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 55.80K | 52W Range | 3.66 - 9.92 |
|
|
|
|
| Nam Tai Property Inc., through its subsidiaries, owns, develops, and operates technology parks in the People's Republic of China. It focuses on developing three parcels of land in Gushu and Guangming, Shenzhenn into technology parks, as well as rents properties. The company was formerly known as Nam Tai Electronics, Inc. and changed its name to Nam Tai Property Inc. in April 2014. Nam Tai Property Inc. was founded in 1975 and is headquartered in Shenzhen, the People's Republic of China. |
|
|
 |
| Market Cap | 738.43M | EPS (ttm) | 0.05 |
| P/E | 465.66 | EPS this Y | - |
| Forward P/E | - | EPS next Y | - |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | 3.14 | EPS Q/Q | -134.80% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 3.57% | Inst Own | 70.00% |
| Insider Trans | 0.00% | Inst Trans | 3.37% |
| Short Float | 5.85% | Earnings | - |
| Analyst Recom | - | Target Price | - |
| Avg Volume | 2.15M | 52W Range | 9.50 - 25.30 |
|
|
|
|
| DiamondPeak Holdings Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2018 and is based in New York, New York. |
|
|
 |
| Market Cap | 788.77M | EPS (ttm) | 1.60 |
| P/E | 10.16 | EPS this Y | 13.90% |
| Forward P/E | 8.39 | EPS next Y | 4.70% |
| PEG | 5.91 | EPS past 5Y | -19.40% |
| P/S | 0.89 | EPS next 5Y | 1.72% |
| P/B | 1.43 | EPS Q/Q | 132.80% |
| Dividend | - | Sales Q/Q | 26.90% |
| Insider Own | 4.90% | Inst Own | 84.00% |
| Insider Trans | 1.08% | Inst Trans | 1.32% |
| Short Float | 0.49% | Earnings | Aug 04/a |
| Analyst Recom | 1.70 | Target Price | 18.00 |
| Avg Volume | 284.89K | 52W Range | 5.66 - 16.47 |
|
|
|
|
| Green Brick Partners, Inc. operates as a homebuilding and land development company in the United States. It operates in three segments: Builder operations Central, Builder operations Southeast, and Land development. The company is involved in the land acquisition and development, entitlements, design, construction, title and mortgage services, marketing, and sale of townhomes, patio homes, single family homes, and luxury homes in residential neighborhoods and master planned communities; development and sale of lots; and land and construction financing business. It owns or controls approximately 9,000 home sites in Dallas, Atlanta, and Vero Beach. The company sells its homes through sales representatives and independent real estate brokers. Green Brick Partners, Inc. is based in Plano, Texas. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Farris John R | Director | Mar 19 | Buy | 6.52 | 6,000 | 39,090 | 128,870 | Mar 20 04:16 PM | | Brandler Harry | Director | Mar 18 | Buy | 5.93 | 2,000 | 11,860 | 29,176 | Mar 19 04:06 PM | | Brandler Harry | Director | Mar 16 | Buy | 6.69 | 5,000 | 33,450 | 27,176 | Mar 18 04:09 PM | | Farris John R | Director | Mar 16 | Buy | 6.22 | 2,400 | 14,928 | 122,870 | Mar 17 05:30 PM | | Farris John R | Director | Mar 13 | Buy | 8.04 | 10,000 | 80,400 | 120,470 | Mar 17 05:30 PM |
|
|
|
 |
| Market Cap | 1.05B | EPS (ttm) | -1.82 |
| P/E | - | EPS this Y | -130.20% |
| Forward P/E | - | EPS next Y | -15.30% |
| PEG | - | EPS past 5Y | - |
| P/S | 53.84 | EPS next 5Y | - |
| P/B | - | EPS Q/Q | 382.30% |
| Dividend | - | Sales Q/Q | -54.30% |
| Insider Own | 3.20% | Inst Own | - |
| Insider Trans | 0.00% | Inst Trans | - |
| Short Float | 1.10% | Earnings | - |
| Analyst Recom | 1.70 | Target Price | 36.00 |
| Avg Volume | 384.77K | 52W Range | 15.21 - 30.49 |
|
|
| Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California. |
|
|
 |
| Market Cap | 82.10M | EPS (ttm) | 0.12 |
| P/E | 47.46 | EPS this Y | 114.60% |
| Forward P/E | - | EPS next Y | - |
| PEG | 4.75 | EPS past 5Y | -24.90% |
| P/S | 0.85 | EPS next 5Y | 10.00% |
| P/B | 1.95 | EPS Q/Q | 803.40% |
| Dividend | - | Sales Q/Q | 7.80% |
| Insider Own | 22.40% | Inst Own | 9.00% |
| Insider Trans | -0.58% | Inst Trans | 8.02% |
| Short Float | 1.23% | Earnings | - |
| Analyst Recom | - | Target Price | 7.25 |
| Avg Volume | 113.76K | 52W Range | 1.43 - 6.18 |
|
|
|
|
| Lifeway Foods, Inc. produces and markets probiotic-based products in the United States and internationally. Its primary product is drinkable kefir, a cultured dairy product in various organic and non-organic sizes, flavors, and types, including low fat, non-fat, whole milk, protein, and BioKefir. The company also offers European-style soft cheeses; cream and other products; ProBugs, a line of kefir products designed for children; cupped kefir and Icelandic Skyr, a line of strained kefir and yogurt products; and frozen kefir in soft serve and pint-size containers. It sells its products primarily through direct sales force, brokers, and distributors. Lifeway Foods, Inc. was founded in 1986 and is based in Morton Grove, Illinois. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SMOLYANSKY EDWARD | Chief Operating Officer | Sep 09 | Sale | 5.87 | 8,000 | 46,948 | 1,511,053 | Sep 11 03:59 PM | | SMOLYANSKY EDWARD | Chief Operating Officer | Aug 21 | Sale | 5.75 | 3,000 | 17,250 | 1,519,053 | Aug 21 02:22 PM | | SMOLYANSKY EDWARD | Chief Operating Officer | Aug 20 | Sale | 5.53 | 8,000 | 44,240 | 1,522,053 | Aug 21 02:22 PM | | SMOLYANSKY EDWARD | Chief Operating Officer | Aug 19 | Sale | 4.45 | 5,000 | 22,250 | 1,530,053 | Aug 21 02:22 PM | | SMOLYANSKY JULIE | President and CEO | Aug 18 | Buy | 4.16 | 3,100 | 12,883 | 1,830,451 | Aug 19 05:04 PM |
|
|
|
 |
| Market Cap | 587.69M | EPS (ttm) | 0.50 |
| P/E | 35.85 | EPS this Y | -2.00% |
| Forward P/E | 23.85 | EPS next Y | 44.23% |
| PEG | 3.59 | EPS past 5Y | 27.60% |
| P/S | 2.67 | EPS next 5Y | 10.00% |
| P/B | 7.95 | EPS Q/Q | -82.40% |
| Dividend | 1.79% | Sales Q/Q | -54.00% |
| Insider Own | 71.10% | Inst Own | 14.30% |
| Insider Trans | 0.00% | Inst Trans | -0.76% |
| Short Float | 3.82% | Earnings | Jul 29/b |
| Analyst Recom | 3.00 | Target Price | 11.50 |
| Avg Volume | 63.14K | 52W Range | 6.77 - 18.65 |
|
|
|
|
| Marine Products Corporation designs, manufactures, and sells recreational fiberglass powerboats for the sportboat, jet boat, and sport fishing markets worldwide. It offers Chaparral sterndrive pleasure boats, including SSi Sport, Ski and Fish Boats, SSX Sport Boats, and the Surf Series; Chaparral outboard pleasure boats within the SSi and SSX, SunCoast, and OSX Sport Luxury models; Robalo outboard sport fishing boats; and Vortex jet boats under the Chaparral brand name. The company also provides center consoles, dual consoles, and Cayman Bay Boats under the Robalo brand name. It sells its products to a network of 195 domestic and 93 international independent authorized dealers. Marine Products Corporation was founded in 1965 and is based in Atlanta, Georgia. |
|
|
 |
| Market Cap | 183.32M | EPS (ttm) | 1.68 |
| P/E | 19.70 | EPS this Y | 202.60% |
| Forward P/E | 11.05 | EPS next Y | 29.87% |
| PEG | - | EPS past 5Y | -22.00% |
| P/S | 0.04 | EPS next 5Y | - |
| P/B | 2.81 | EPS Q/Q | - |
| Dividend | - | Sales Q/Q | -0.70% |
| Insider Own | 1.30% | Inst Own | 23.20% |
| Insider Trans | -24.68% | Inst Trans | 47.98% |
| Short Float | 1.94% | Earnings | Sep 10/a |
| Analyst Recom | 2.00 | Target Price | 24.50 |
| Avg Volume | 45.68K | 52W Range | 7.47 - 33.15 |
|
|
|
|
| A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company worldwide. It operates through Wholesale Trading & Ancillary Services, Secured Lending, and Direct Sales segments. The company provides gold, silver, platinum, and palladium in the form of bars, plates, powder, wafers, grains, ingots, and coins, as well as distributes gold and silver coins and bars from sovereign and private mints. It also offers financing and other services relating to the purchase and sale of bullion and numismatics; provides storage solutions for precious metals and numismatic coins for financial institutions, dealers, investors, and collectors; and offers a range of logistics services, including storage, shipping, handling, receiving, processing, packing, and inventorying of precious metals and custom coins. In addition, the company provides custom fabricated gold and silver bullion and other specialty products, as well as various services comprising consignment and customized finance programs. It serves mints, manufacturers and fabricators, refiners, coin and bullion dealers, e-commerce retailers, banks and other financial institutions, commodity brokerage houses, retail customers, industrial users of precious metals, investors, and collectors. The company was founded in 1965 and is headquartered in El Segundo, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| RAVICH JESS M | Director | May 21 | Sale | 16.55 | 1,633 | 27,020 | 155,625 | May 22 04:37 PM | | RAVICH JESS M | Director | May 19 | Sale | 16.30 | 1,948 | 31,759 | 158,706 | May 20 07:06 PM | | RAVICH JESS M | Director | May 18 | Sale | 16.55 | 500 | 8,275 | 159,206 | May 20 07:06 PM | | RAVICH JESS M | Director | May 15 | Sale | 16.20 | 2,000 | 32,400 | 159,706 | May 18 06:00 PM | | RAVICH JESS M | Director | May 14 | Sale | 16.07 | 5,149 | 82,752 | 161,706 | May 15 05:53 PM |
|
|
|
 |
| Market Cap | 1.51B | EPS (ttm) | -1.58 |
| P/E | - | EPS this Y | 12.40% |
| Forward P/E | - | EPS next Y | -15.20% |
| PEG | - | EPS past 5Y | -42.90% |
| P/S | - | EPS next 5Y | 19.93% |
| P/B | 4.39 | EPS Q/Q | -3.40% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 0.10% | Inst Own | 94.10% |
| Insider Trans | -80.15% | Inst Trans | 32.35% |
| Short Float | 8.30% | Earnings | Aug 06/a |
| Analyst Recom | 1.80 | Target Price | 25.63 |
| Avg Volume | 611.14K | 52W Range | 6.35 - 28.00 |
|
|
|
|
| Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| WILSON TROY EDWARD | President and CEO | Sep 10 | Option Exercise | 6.15 | 37,030 | 227,735 | 65,126 | Sep 10 06:05 PM | | WILSON TROY EDWARD | President and CEO | Sep 10 | Sale | 28.00 | 37,030 | 1,036,840 | 28,096 | Sep 10 06:05 PM | | WILSON TROY EDWARD | President and CEO | Sep 10 | Sale | 28.00 | 1,025 | 28,700 | 305,711 | Sep 10 06:05 PM | | GRASSO MARC | CFO, CBO | Sep 08 | Option Exercise | 15.47 | 10,000 | 154,700 | 10,000 | Sep 10 06:04 PM | | GRASSO MARC | CFO, CBO | Sep 08 | Sale | 26.00 | 10,000 | 260,000 | 0 | Sep 10 06:04 PM |
|
|
|
|
12345678next
|
|
|
